

06 18 2003

U.S. Patent and Trademark Office
INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Use as many sheets as necessary.

| | |
|---------|------|
| Sheet 1 | of 1 |
|---------|------|

Complete if Known

| | |
|------------------------|-------------------------|
| Application Number | 09 954 679 |
| Filing Date | September 12, 2001 |
| First Named Inventor | Donna T Ward |
| Group Art Unit | 1635 |
| Examiner Name | Karen A Lacourciere |
| Attorney Docket Number | ISIS0058-100 (RTS-0212) |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials: **KL** Cite No: **1** Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages, volume/issue number(s), publisher, city and/or country where published.

SLERIAN et al "2'-5'-Oligoadenylate-Antisense Chimeras as Experimental Therapeutic Agents for Cancer and Viral Infections." Antisense & Nucleic Acid Drug Development 10(3):640-643

RECEIVED

AUG 22 2003

TECH CENTER 1600/2900

Examiner Signature:

Karen Lacourciere

Date Considered:

11-12-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This citation of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file and/or have the USPTO process an application. Confidentiality is guaranteed by 35 U.S.C. 122 and 37 CFR 1.14. This citation is estimated to take 12 minutes to complete. By making a photocopy and submitting the completed application form to the USPTO, you will be responding upon the individual representations made on the amount of time you require to complete this form and/or suggestions for reducing it. It is further understood and agreed that the above named inventor(s) and assignee(s) are to receive all benefits resulting from such action taken by the USPTO in respect of this application based on the information contained in this form. The USPTO will not be bound by any statements or arguments contained herein but will determine what action, if any, is to be taken in the prosecution of this application based on the facts and the law.

FEES OR COMPLETED FORMS TO THIS ADDRESS: SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.